Biopep Solutions is focused on the development of BPS-001, a lead drug that has shown promising results in preclinical studies against various cancer types, particularly prostate cancer. The drug has demonstrated efficacy in inhibiting tumor growth in multiple prostate cancer cell lines, including LNCaP, PC3, and 22RV1, as well as in a transgenic tumor model, TRAMP-C2, and a triple-negative breast cancer model, MDA MD 231. Notably, BPS-001 exhibits multiple anticancer mechanisms of action, which may reduce the likelihood of tumor resistance compared to existing androgen receptor inhibitors. The company is advancing BPS-001 towards clinical development, specifically targeting metastatic, castration-resistant prostate cancer (mCRPC) as its first indication.

In addition to its preclinical successes, Biopep Solutions is preparing to initiate a phase 1/2 clinical trial to evaluate the safety and preliminary anticancer activity of BPS-001 in solid tumors, with a focus on prostate, breast, and ovarian cancers. The clinical trial will be conducted at reputable cancer centers, including the Levine Cancer Institute, the Winship Cancer Center at Emory University, and the British Columbia Cancer Agency. This strategic approach underscores the company's commitment to advancing innovative therapeutic products for cancer treatment and addressing unmet medical needs in oncology.

United States

Biopep Solutions Inc. is a privately owned, late pre-clinical stage biotechnology company that discovers and develops innovative therapeutic products for the treatment of cancers and other diseases. The Company’s lead product, BPS-001, is a heterogeneous biologic extract containing a known composition of multiple peptide and protein components. BPS-001 has the potential to treat a wide variety of cancers and diseases.

Biopep Solutions

Company Details